World Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
29(32), P. 4831 - 4850
Published: Aug. 24, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
causes
significant
global
burden
and
is
a
leading
cause
of
mortality.
NAFLD
induces
myriad
aberrant
changes
in
hepatocytes
at
both
the
cellular
molecular
level.
Although
spectrum
widely
recognised,
precise
triggers
for
progression
are
still
to
be
fully
elucidated.
Furthermore,
propagation
cirrhosis
poorly
understood.
Whilst
some
progress
terms
treatment
options
have
been
explored,
an
incomplete
understanding
hepatic
alterations
limits
their
clinical
utility.
We
therefore
reviewed
key
pathways
responsible
pathogenesis
such
as
innate
adaptative
immunity,
lipotoxicity
fibrogenesis,
highlighted
current
trials
patients.
The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2024,
Volume and Issue:
unknown
Published: April 18, 2024
Abstract
Context
PNPLA3
is
a
promising
target
for
the
treatment
of
metabolic
dysfunction–associated
steatotic
liver
disease.
ARO-PNPLA3
drug
that
efficiently
lowers
expression
in
hepatocytes
at
mRNA
level,
resulting
significant
reduction
fat
Phase
I
clinical
trials.
However,
long-term
effects
and
potential
side
are
not
well
understood.
Objective
We
conducted
2-sample,
2-step
Mendelian
randomization
analysis
to
investigate
association
between
inhibition
10
cardiovascular
diseases
(CVDs),
as
role
lipid
traits
mediators.
Methods
identified
genetic
variants
near
gene,
which
linked
percentage,
instrumental
variables
inhibiting
PNPLA3.
Additionally,
positive
control
analyses
on
were
validate
selection
instruments.
Results
Genetically
predicted
significantly
increased
risk
coronary
atherosclerosis
(1.14,
95%
CI
1.06,
1.23),
heart
disease
1.08,
1.21),
myocardial
infarction
(1.16,
1.26).
Suggestive
associations
observed
failure
(1.09,
1.02,
1.17,
P
=
.0143)
atrial
fibrillation
(1.17,
1.00,
1.36,
.0468).
Blood
low-density
lipoprotein
cholesterol
(LDL-C)
total
(TC)
mediated
approximately
16%
25%,
30%,
14%
22%
atherosclerosis,
infarction,
disease,
respectively.
Conclusion
This
study
suggests
increases
major
CVDs.
Moreover,
blood
LDL-C
TC
may
mediate
proportion
or
infarction.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: March 13, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
an
emerging
global
health
concern
with
limited
therapeutic
options.
Multivitamins,
widely
consumed
dietary
supplements,
have
been
proposed
to
modulate
oxidative
stress
and
inflammation,
potentially
impacting
MASLD
progression.
However,
their
efficacy
in
reducing
mortality
other
complications
remains
unclear.
Using
data
from
the
UK
Biobank
7
years
of
median
follow-up
period,
this
study
assessed
association
between
multivitamin
use
outcomes,
including
all-cause
mortality,
liver-related
cardio-cerebrovascular
(CVD),
chronic
kidney
(CKD),
individuals
those
without
disease.
Inverse
probability
treatment
weighting
(IPTW)
was
employed
adjust
for
confounders.
Multivitamin
users
showed
a
significantly
lower
risk
cohort
both
before
(HR:
0.88,
95%
CI
0.81–0.95,
P
=
0.034)
after
0.94,
0.88–1.00,
0.037)
IPTW
adjustment.
also
associated
CVD
0.72,
0.68–0.76,
<
0.001)
CKD
0.73,
0.67–0.81,
cohort.
No
significant
reduction
found
or
cirrhosis
incidence.
These
findings
suggest
that
multivitamins
might
provide
broader
protective
effects
populations
metabolic
dysfunction.
Further
research
needed
clarify
role
liver-specific
outcomes.
World Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
29(32), P. 4831 - 4850
Published: Aug. 24, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
causes
significant
global
burden
and
is
a
leading
cause
of
mortality.
NAFLD
induces
myriad
aberrant
changes
in
hepatocytes
at
both
the
cellular
molecular
level.
Although
spectrum
widely
recognised,
precise
triggers
for
progression
are
still
to
be
fully
elucidated.
Furthermore,
propagation
cirrhosis
poorly
understood.
Whilst
some
progress
terms
treatment
options
have
been
explored,
an
incomplete
understanding
hepatic
alterations
limits
their
clinical
utility.
We
therefore
reviewed
key
pathways
responsible
pathogenesis
such
as
innate
adaptative
immunity,
lipotoxicity
fibrogenesis,
highlighted
current
trials
patients.